Mounjaro users panic over massive price hikes - experts reveal how to keep using weight loss jabs... for less
The US pharmaceutical giant announced the cost would soar from September 1, with the wholesale price of a month's supply of the highest dose rising from £122 to £330.
Lilly claimed it had initially launched Mounjaro in the UK at a price 'significantly below the European average to prevent delays in NHS availability' but that this must now change 'to ensure fair global contributions to the cost of innovation'.
The announcement, however, does not affect the price the NHS pays, as the service has negotiated a heavily discounted rate for those getting the drug on prescription.
But there are thought to be around 1.5 million people on weight loss drugs in the UK with more than half of them on Mounjaro—and estimates suggest nine in 10 pay for these drugs privately.
Users flocked to social media warning denouncing the move, worried they were now left with no option but to come off the 'life changing' jab.
'I have no one to talk to about this and I'm freaking out,' one wrote on Reddit.
'Call it dramatic but I just cannot afford this, and this med is my only lifeline right now. I'm absolutely devastated. I don't know what to do.'
Mounjaro price increases
Mounjaro®▼ (tirzepatide) KwikPen® Dose Current UK List Price New UK List Price (From September)
2.5mg £92 £133
5mg £92 £180
7.5mg £107 £255
10mg £107 £255
12.5mg £122 £330
15mg £122 £330
Another said: 'I'm totally freaking out about it! I'm only about to go onto my 2nd pen now. The black market is going to be even more rife than ever due to this, fuming.'
The main concern among slimmers is regaining weight after being forced to stop Mounjaro.
Evidence suggests currently only around 2 to 10 per cent of people keep all their lost weight off if they stop taking the jabs, known collectively as GLP-1s.
So is it possible to still access Mounjaro at a similar price? And crucially, what are options if you want to stay on the jabs but can't afford to?
With the help of a team of experts, we explain everything you need to know about how to keep using weight loss jabs, for less...
I already pay for Mounjaro privately - can I now get it on the NHS?
Not necessarily. Only those who hit the body mass index (BMI) threshold set by the NHS may be prescribed weight-loss jabs.
Patients must have a BMI of at least 40—severely obese—as well as four obesity-related conditions, including high blood pressure, high cholesterol, sleep apnoea, heart disease, osteoarthritis or diabetes.
Next year, those with a BMI of over 35, along with four obesity-related conditions, will be offered the jabs. Then, in September 2026, those with a BMI of over 40 and just three related conditions will be able to access them on the NHS.
Private clinics, however, can offer Mounjaro to patients with a BMI of over 30 or 27 if they also have at least one weight-related condition.
'There are lots of patients paying privately who want to switch to NHS treatment,' says Oxford GP Dr Helen Salisbury, 'but that won't happen overnight.'
If I qualify for Mounjaro on the NHS, what are my next steps?
Eligible patients need to make an appointment with their GP, which will likely be face-to-face in an effort to combat 'potential misuse'.
The GP will assess medical records and, if necessary, contact other doctors who have recently treated the patient, to make sure they are a suitable candidate for treatment.
If the prescription is approved, then patients will initially need to have monthly face-to-face appointments with a 'suitably trained healthcare professional', such as a nurse and monitored for potential side effects.
GPs need to regularly review the patient's prescription, taking into account their BMI, comorbidities, side effects, and mental health, for at least the first year of treatment and possibly longer.
I'm not eligible but can't afford to stay on Mounjaro from September—what are my options?
Thousands of Mounjaro users could face a situation by the end of the month where they cannot afford to continue taking Mounjaro.
But experts say it is possible to switch medication and begin a new weight loss jab.
Thorrun Govind, a TV pharmacist and former chair of the Royal Pharmaceutical Society, told the Daily Mail: 'Patients can ask their provider to switch and a decision will then be taken together.'
Toby Nicol, CEO at private weight loss jab provider CheqUp, meanwhile said: 'A huge number of people will be considering switching and it's important that they know that this is absolutely possible.
'Wegovy is now a much more affordable option and is also clinically proven as a highly effective drug.
'We don't want anyone to be priced out and think they have to take something which is unsafe.
'Do not buy from the cowboys. If the price is to good to be true, it probably is.'
Experts, however, have warned against trying to 'microdose' remaining Mounjaro pens in an effort to prolong the drug and save money.
The term, refers to counting clicks on pre–filled Mounjaro pens to deliver less than the prescribed dose—or even breaking them open.
'People are risking serious side effects from overdosing, as well as the potential for life–threatening infection,' said Professor Alex Miras, an endocrinologist at Ulster University. 'We cannot endorse it.'
He added: 'Not only is contamination a risk, but it also reduces the effectiveness of the medication.'
So which jab should I switch to?
Pharmacists have said Wegovy is the most likely option. The drug, which contains the ingredient semaglutide, is made by Danish pharmaceutical giant Novo Nordisk.
Kevin Joshua, the clinical lead at Juniper, an online pharmacy selling weight-loss jabs, said: 'For many, the pragmatic move is to switch to Wegovy—proven outcomes, a cardiovascular risk‑reduction indication in people living with overweight or obesity, and more predictable private costs.'
Clinical trials have shown Mounjaro is the most effective of all the injections, with average weight loss of 20 per cent over 72 weeks.
By comparison, Wegovy achieved average weight loss of around 14 per cent.
Experts suggest this is because Wegovy mimics one hormone released by the body after a meal, to flip one appetite switch in the brain. Mounjaro, meanwhile, flips two.
How can I make the switch safely?
Given the two jabs contain different ingredients, how well the body tolerates them may differ.
As with any medication, patients may need to adjust to the side effects of a new medicine.
Dr Suhail Hussain, a GP for private online clinic Doctify, said: 'Mounjaro tends to be better tolerated in terms of gastrointestinal side effects than Wegovy, so patients may experience more nausea or vomiting.'
Other common side effects of beginning a new GLP-1 medication includes nausea, diarrhoea, constipation and headaches.
Ms Govind told Daily Mail that one way patients may make the switch is by 'taking your next semaglutide dose one week after your last Mounjaro injection, effectively replacing it without a break'.
She added: 'This avoids a "hunger rebound" that can happen if you leave a long gap.
'There is no direct dose conversion between tirzepatide and semaglutide. So you might switch to a low dose semaglutide and then go up in dose.'
Should I come off Mounjaro completely first before starting a new medication?
Experts have repeatedly warned against completely stopping taking weight loss jabs suddenly over fears of side effects such as body aches, as well as regaining the weight lost on the drug.
But according to pharmacists, patients must first completely come off Mounjaro before switching to a new jab, such as Wegovy.
This is because the GLP-1 jabs affect the same hormones and could 'massively increase the risk of side effects', Ms Govind told the Daily Mail.
There is also not clear long term evidence yet on the long term issues this could cause, she added.
'For patients who are currently on Mounjaro, it may require a period of abstinence of several weeks before switching on an alternative,' Dr Leyla Hannbeck also told the Daily Mail.
'Your pharmacist will be able to advise you on the switch.'
Ms Govind added: 'Typically it's seven days between the last tirzepatide and the first semaglutide dose.
'But it depends on the side effects that the patient has experienced and their tolerability to those side effects.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Record
20 minutes ago
- Daily Record
NHS Lanarkshire first Scots health board to appoint permanent Promise Development Officer
Beth-Anne McDowall has joined the organisation, which is committed to ensuring that all care-experienced people have the support they need if they have healthcare needs. NHS Lanarkshire is the first health board in Scotland to have a permanent Promise Development Officer. Beth-Anne McDowall has joined the organisation, which is committed to ensuring that all care-experienced people have the support they need if they have healthcare needs. Beth-Anne's role is to support NHS Lanarkshire to keep The Promise, through continuously learning about what creates change, and helping changes to be implemented. This includes ensuring that healthcare staff can provide the support children and young people in the care system need to grow up loved, safe and respected. It also applies to adults who have experienced the care system. Beth-Anne said: "This is the first Promise-centric post in an NHS health board. "My role will involve many things, for me, the primary function of my role is to ensure care-experienced people within Lanarkshire contribute, design, influence and shape the services they receive from us to ensure they meet their needs and that they are supported to thrive. "Keeping The Promise is everyone's responsibility, not just social work or a local authority. "This specific post demonstrates NHS Lanarkshire's commitment that all care-experienced people grow up loved, safe and respected, so that they can realise their full potential. "It is also a concrete commitment given as not only have NHS Lanarkshire created this post, they have made it permanent, ensuring that we will continuously adapt and evolve as the needs of the care community change. "It is fitting that I have been successful in securing the post given that I not only worked at The Independent Care Review to help shape the conclusions of The Promise, and in various other national roles but I, myself, am care-experienced and from Lanarkshire so I'm really attuned to the needs of the care community." Trudi Marshall, executive nurse director, added: "We are delighted to welcome Beth-Anne to NHS Lanarkshire. "The introduction of this post demonstrates our commitment to ensuring that the children and young people in Lanarkshire who have experienced care are supported to realise their full potential and that they grow up loved, safe and respected. "Working in collaboration with our local councils and health and social care partnerships we have already made significant progress in implementation of The Promise. "Beth-Anne will now support us to continue this work and ensure that we keep the voice of the community central to our work in NHS Lanarkshire." Beth-Anne brings a wealth of experience to this role. Not only has she experienced the care system first hand, she has been championing the rights of care-experienced children and adults for more than 10 years. She has worked on the front lines in local government and a national children's charity. Her outstanding contributions earned her a YouthLink Scotland Award in 2018 and a YoungScot Award in 2022. Remarkably, Beth-Anne became Scotland's youngest non-executive director at just 19, serving on the Children's Hearings Scotland board for over eight years and is now a board member with the Mental Welfare Commission.
Daily Mail
21 minutes ago
- Daily Mail
How to switch from Mounjaro to Wegovy WITHOUT risking weight gain, reveals top GP - as 'King Kong' jab is set to TRIPLE in price
A leading GP has issued guidance to patients on how to safely switch between weight loss drugs—as prices of the popular jab Mounjaro are set to soar. Dr Donald Grant, GP and Senior Clinical Advisor at The Independent Pharmacy, warned it is 'crucial' to transition under medical supervision in order to limit severe side effects and weight gain. His statement comes as CheqUp, one of the UK's largest providers of weight-loss treatments, reports sales of rival treatment Wegovy have jumped by more than 500 per cent in recent days as patients seek alternatives. Dr Donald Grant, GP and Senior Clinical Advisor at The Independent Pharmacy, said: 'As people consider potentially swapping Mounjaro for Wegovy, it's essential to understand the safe ways of transitioning between these two treatments. 'This can limit drastic side effects and avoid progress from plateauing.' 'It's crucial for people on these treatments to maintain open and honest conversations with their prescribing clinician or GP, who can provide tailored advice based on medical history and prior doses. 'You can't make a direct 'mg-for-mg' switch between Mounjaro and Wegovy because they are different drugs with different strengths. 'Instead, a medical professional will take a dose conversion approach, and if you make the decision to move, they will support you through this.' Mounjaro price increases Mounjaro®▼ (tirzepatide) KwikPen® Dose Current UK List Price New UK List Price (From September) 2.5mg £92 £133 5mg £92 £180 7.5mg £107 £255 10mg £107 £255 12.5mg £122 £330 15mg £122 £330 Earlier this month, Eli Lilly confirmed that the price of its blockbuster weight-loss jab Mounjaro will rise steeply for British patients from September 1. The drug, which is prescribed to around 90 per cent of people in the UK using weight-loss injections, will see the cost of its highest dose, 15mg, soar from £122 to £330 a month—a 170 per cent increase. Even mid-range doses such as the 5mg pen will jump from about £92 to £180, with an average rise across the range of 126 per cent. In the UK private market, Wegovy is generally cheaper. A 2.4 mg maintenance dose of Wegovy costs around £250 to £300 per month. At the lower end, Wegovy's starter dose is priced around £120 to £170. In clinical trials, Mounjaro has been shown to deliver the greatest weight loss of any licensed drug, with patients losing on average up to 22.5 per cent of their body weight over 72 weeks at the highest dose. By comparison, Wegovy patients lose up to 17.5 per cent over the same period on the full 2.4mg dose. Toby Nicol, CEO at CheqUp, said: 'As news of the Mounjaro price rise spreads, weight loss jab patients are voting with their wallets and making the switch to Wegovy, which is nearly as effective but has a considerably lower cost. 'We've been blown away by the huge spike in demand for Wegovy. It is too early to say for sure, but Wegovy will probably become the most popular weight loss treatment in the UK as patients switch from Mounjaro.' Superintendent Pharmacist Aaron Arman also stressed the importance of proper medical oversight: 'Both Mounjaro and Wegovy work in similar ways and are proven to be highly effective. 'For patients unable to afford the increase in price, it is possible to switch from Mounjaro to Wegovy, though the dose they can switch to will depend on the Mounjaro dose they are currently on.' CheqUp's research found as many as 80 per cent of current Mounjaro users will either switch or come off the drug entirely—an estimated 625,000 patients—while more than 325,000 say they have been priced out of treatment. Nicol added: 'A huge number of people will be considering switching and it's important they know that while this is absolutely possible, doing so under the supervision of a trusted pharmacist is a must. 'Simply stopping one treatment and moving to the other without due care can have serious health consequences.' Concerns are also mounting that so-called 'cowboy' operators will exploit the situation. Nicol warned: 'Black markets are going to try and exploit this situation. 'Go on any social media site and you can find cowboy operators in minutes—drug dealers, for all intents and purposes—taking advantage of confused patients who can no longer afford treatment but want to continue. As with most things in life, if it's too good to be true, it probably is.'
Reuters
an hour ago
- Reuters
Shares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment
COPENHAGEN, DENMARK, Aug 18 (Reuters) - Shares in Novo Nordisk ( opens new tab rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver condition, positive news for the drugmaker that lost more than one-third of its market value in recent weeks. Novo's shares rose as much as 5% at opening and were trading 3.5% higher by 0711 GMT. Three weeks ago, investors wiped $70 billion off its market value, after Novo - which became Europe's most valuable listed company following the launch of Wegovy in 2021 - issued a profit warning and named a company veteran as new CEO. On Friday, the U.S. Food and Drug Administration granted accelerated approval for Wegovy to treat metabolic dysfunction-associated steatohepatitis, or MASH, making it the first GLP-1 class therapy cleared for the progressive liver condition that affects around 5% of adults in the United States. Rival Eli Lilly (LLY.N), opens new tab has published encouraging MASH data in a mid-stage trial with tirzepatide - the active ingredient in its popular diabetes drug Mounjaro and weight-loss treatment Zepbound. "It is expected that this market exclusivity will only last for a transitional phase before Eli Lilly also launches a product on the market," said Nordnet analyst Per Hansen. Novo has also applied this year for approval in Europe and Japan. Its shares have lost more than two-thirds of their value since June last year, amid concerns that the Danish drugmaker is losing ground in the obesity drug race it started to rival Eli Lilly and "compounded" copycat drugs.
